INACTIVE/DISSOLVED
Founded
10 Mar 2005
Address
Clarus Ventures LLC
One Memorial Drive
Suite 1230
Cambridge, MA 02142
United States
Phone
Website
VCID: 30972
Profile
Corporate information
Official name
Clarus Ventures LLC
Renamed to
Official name
Clarus Ventures LLC
Renamed to
Investment activity status
Not investing
Company type
Life sciences venture capital firmFunds managed
| Fund | Type | Vintage |
|---|---|---|
| Clarus IV-A LP | Venture | 2017 |
| Clarus IV-B LP | Venture | 2017 |
| Clarus IV-C LP | Venture | 2017 |
| Clarus IV-D LP | Venture | 2017 |
| Clarus DE II LP | Venture | 2014 |
| Clarus Defined Exit I LP | Venture | 2014 |
| Clarus Lifesciences III LP | Venture | 2014 |
| Clarus Ventures III GP LP | Venture | 2014 |
| Clarus Lifesciences II LP | Venture | 2008 |
| Clarus Lifesciences I LP | Venture | 2006 |
| Clarus Ventures II | Venture |
Funding
Funding rounds
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
The Blackstone Group LP | Private equity firm | United States | Led the round. |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
The Blackstone Group LP Private equity firm |
+1 (212) 583-5000 |
Acquisition |
Investments
Investment preferences
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Oxford Immunotec Ltd |
United Kingdom | 1 Apr 2010 18 Jun 2012 |
Venture Round participant. Active |
|
|
|
Flowonix Medical A medical device company dedicated to helping those who suffer from chronic disorders. |
United States | 1 May 2012 | N/A |
|
|
|
Catabasis Pharmaceuticals Inc |
United States | 1 Apr 2010 1 Dec 2011 |
Series A |
|
|
NanoString Technologies Inc A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. |
United States | 1 Jun 2009 1 Nov 2011 |
Series D Active |
|
|
|
Cleave Biosciences Inc Drug development company focused on novel targets in cellular protein homeostasis pathways |
United States | 1 Oct 2011 | Series A Active |
|
|
|
SARcode Bioscience Inc |
United States | 1 Jul 2011 | Series B |
|
|
|
Aerie Pharmaceuticals Inc |
United States | 1 Mar 2011 | Series B Active |
|
|
|
TyRx Inc |
United States | 1 Dec 2010 | N/A |
|
|
|
Pearl Therapeutics Inc Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases |
United States | 1 Feb 2010 | N/A |
|
|
Zogenix Inc A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. |
United States | 1 Sep 2009 | Series B Follow-on investment. Round participant. Active |
|
|
|
Lycera Corp |
United States | 1 Apr 2009 | Series A |
|
|
|
Aerovance Inc |
United States | 1 Apr 2009 | N/A Active |
|
|
|
Heptares Therapeutics Ltd |
United Kingdom | 1 Feb 2009 | Series A |
|
|
|
Virdante Pharmaceuticals Inc A privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders. |
United States | 31 Dec 2008 | Series A |
|
|
|
Biolex Therapeutics Inc |
United States | 1 Oct 2008 | Series D Active |
|
|
|
Link Medicine Inc Advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases |
United States | 1 Sep 2008 | Series C |
|
|
|
ESBATech AG Switzerland based Biomedical Research Unit of Alcon |
Switzerland | 1 Aug 2008 | Series B Initial investment. Round participant. Active |